Boston Scientific Corporation Heart Device Won’t Get Quick Review From FDA

March 26, 2010 |

1 min read

WSJ -- Regulators on Thursday said they won't speed up the review of manufacturing changes required for Boston Scientific Corp. to resume selling its implantable heart defibrillators.

Regulatory

MORE ON THIS TOPIC

Vaccine and syringe injection. Doctor hand with syringe. Vaccination of people for prevention, immunization and treatment from virus infection. Medicine, flu shot, test with needle. Vector

Vaccines

FDA Clears Updated COVID-19 Shots From Pfizer, Moderna, Novavax—But With Restrictions

August 28, 2025

·

2 min read

·

Tristan Manalac

Susan Monarez speaking to a senator at her confirmation hearing as CDC director

Policy

Monarez Fired From Top CDC Spot Following Friction Over New COVID-19 Vaccine Policy

August 28, 2025

·

3 min read

·

Heather McKenzie

A pit crew working on a race car

Regulatory

The US Is Losing Its Biopharma Edge, Writes Former FDA Commissioner

August 27, 2025

·

3 min read

·

Dan Samorodnitsky

Contemporary art collage of target and hands with the megaphone on a ue background with copy space. Concept of reaching a goal and spreading.

Rare diseases

Regeneron Eyes 2026 Filing for siRNA Myasthenia Gravis Drug After Phase III Win

August 27, 2025

·

2 min read

·

Tristan Manalac